Alberta Investment Management Corp (AIMCo)
NTLA icon

Alberta Investment Management Corp (AIMCo)’s Intellia Therapeutics NTLA Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,600
Closed -$298K – 783
2017
Q2 		$298K Sell
18,600
-31,600
-63% -$442K ﹤0.01% 687
2017
Q1 		$707K Buy
+50,200
New +$674K 0.01% 652

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s NTLA Position: Q3 2017 in Review

Alberta Investment Management Corp (AIMCo) sold out of Intellia Therapeutics (NTLA) in Q3 2017, closing a stake of 18,600 shares — an estimated $298K sold.

Alberta Investment Management Corp (AIMCo) first reported a position in NTLA in Q1 2017 and held it in 2 quarters. The position peaked at $707K in Q1 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q3 2017.

  • Alberta Investment Management Corp (AIMCo) reported no remaining Intellia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Alberta Investment Management Corp (AIMCo) sold 18,600 Intellia Therapeutics shares in Q3 2017, an estimated $298K.
  • Alberta Investment Management Corp (AIMCo) first reported a position in Intellia Therapeutics in Q1 2017 and held it in 2 quarters.
  • Alberta Investment Management Corp (AIMCo)'s Intellia Therapeutics position peaked at $707K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2017.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q3 2017, filed 14 Nov 2017.